© 2004 by Oxford University Press
© 2004 Oxford University Press
ARTICLE |
Effect of Imatinib Mesylate on Neuroblastoma Tumorigenesis and Vascular Endothelial Growth Factor Expression
Affiliation of authors: Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Correspondence to: Carol J. Thiele, PhD, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Dr., MSC 1298, Bldg. 10/13N240, Bethesda, MD 20892 (e-mail: ct47a{at}nih.gov)
Background: Alternative treatment options are needed for advanced neuroblastoma patients because their prognosis remains poor after intensive chemotherapy. Neuroblastoma cells express platelet-derived growth factor (PDGF), stem cell factor (SCF), and vascular endothelial growth factor (VEGF) and their respective receptors, PDGFR, c-Kit, and Flk-1. We therefore evaluated the effects of imatinib mesylate (imatinib), a selective inhibitor of the tyrosine kinase activities of c-Kit and PDGFR, on the growth of neuroblastoma cells in vivo and in vitro. Methods: We tested seven human neuroblastoma cell lines for their sensitivity to imatinib. Cell viability was assessed by trypan blue dye exclusion. Apoptosis was evaluated by nuclear staining, flow cytometry, and western blotting. Protein assays included immunoprecipitation, western blotting, enzyme-linked immunosorbent assays, and immunohistochemistry. mRNA expression was assessed by northern blotting. We used a xenograft model in SCID mice (10 mice per group) to evaluate the effects of imatinib oral therapy (50 or 100 mg/kg every 12 hours for 14 days) on neuroblastoma tumor growth. All statistical tests were two-sided. Results: All seven neuroblastoma cell lines treated with imatinib displayed concentration-dependent decreases in cell viability, which coincided with an induction of apoptosis, and with ligand-stimulated phosphorylation of c-Kit and PDGFR. The imatinib concentrations that caused 50% inhibition of growth and 50% inhibition of ligand-induced phosphorylation of these receptors were 9–13 µM and 0.1–0.5 µM, respectively. Expression of VEGF, but not phosphorylation of Flk-1, its receptor, was reduced in neuroblastoma cells treated with imatinib at 10 µM or higher. Mice treated with imatinib at 50 mg/kg or 100 mg/kg had statistically significantly smaller tumors than control mice treated with vehicle (mean tumor volume in mice treated with imatinib at 50 mg/kg = 1546 mm3, in control mice = 2954 mm3; difference = 1408 mm3, 95% confidence interval [CI] = 657 to 2159 mm3; P<.001; mean tumor volume in mice treated with imatinib at 100 mg/kg = 463 mm3; difference = 2491 mm3, 95% CI = 1740 to 3242 mm3; P<.001). Conclusions: Imatinib inhibited the growth of neuroblastoma cells in vitro and in vivo. This inhibition was associated with suppression of PDGFR and c-Kit phosphorylation and inhibition of VEGF expression.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Mithraprabhu and K. L Loveland Control of KIT signalling in male germ cells: what can we learn from other systems? Reproduction, November 1, 2009; 138(5): 743 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mukherjee, D. Kamnasaran, A. Balasubramaniam, I. Radovanovic, G. Zadeh, T.-R. Kiehl, and A. Guha Human Schwannomas Express Activated Platelet-Derived Growth Factor Receptors and c-kit and Are Growth Inhibited by Gleevec (Imatinib Mesylate) Cancer Res., June 15, 2009; 69(12): 5099 - 5107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. ROSSLER, E. ODENTHAL, B. GEOERGER, A. GERSTENMEYER, J. LAGODNY, C. M. NIEMEYER, and G. VASSAL EGFR Inhibition Using Gefitinib Is Not Active in Neuroblastoma Cell Lines Anticancer Res, April 1, 2009; 29(4): 1327 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Rocconi, K. S. Matthews, K. J. Kimball, M. G. Conner, A. C. Baker, and M. N. Barnes Expression of C-kit and Platelet-Derived Growth Factor Receptors in Ovarian Granulosa Cell Tumors Reproductive Sciences, September 1, 2008; 15(7): 673 - 677. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Vitali, C. Mancini, V. Cesi, B. Tanno, M. Mancuso, G. Bossi, Y. Zhang, R. V. Martinez, B. Calabretta, C. Dominici, et al. Slug (SNAI2) Down-Regulation by RNA Interference Facilitates Apoptosis and Inhibits Invasive Growth in Neuroblastoma Preclinical Models Clin. Cancer Res., July 15, 2008; 14(14): 4622 - 4630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Boller, A. Schramm, K. T. Doepfner, T. Shalaby, A. O. von Bueren, A. Eggert, M. A. Grotzer, and A. Arcaro Targeting the Phosphoinositide 3-Kinase Isoform p110{delta} Impairs Growth and Survival in Neuroblastoma Cells Clin. Cancer Res., February 15, 2008; 14(4): 1172 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bertino, C. Porta, D. Barbone, S. Germano, S. Busacca, S. Pinato, G. Tassi, R. Favoni, G. Gaudino, and L. Mutti Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed Thorax, August 1, 2007; 62(8): 690 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brama, S. Basciani, S. Cherubini, S. Mariani, S. Migliaccio, M. Arizzi, G. Rosano, G. Spera, and L. Gnessi Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment Endocr. Relat. Cancer, March 1, 2007; 14(1): 61 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Matei, M. Satpathy, L. Cao, Y.-C. Lai, H. Nakshatri, and D. B. Donner The Platelet-derived Growth Factor Receptor {alpha} Is Destabilized by Geldanamycins in Cancer Cells J. Biol. Chem., January 5, 2007; 282(1): 445 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Tanno, C. Mancini, R. Vitali, M. Mancuso, H. P. McDowell, C. Dominici, and G. Raschella Down-Regulation of Insulin-Like Growth Factor I Receptor Activity by NVP-AEW541 Has an Antitumor Effect on Neuroblastoma Cells In vitro and In vivo. Clin. Cancer Res., November 15, 2006; 12(22): 6772 - 6780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J Gross, G. Munter, M. Bitan, T. Siegal, A. Gabizon, R. Weitzen, O. Merimsky, A. Ackerstein, A. Salmon, A. Sella, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr. Relat. Cancer, June 1, 2006; 13(2): 535 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Sambol, G. Ambrosini, R. C. Geha, P. T. Kennealey, P. DeCarolis, R. O'Connor, Y. V. Wu, M. Motwani, J.-H. Chen, G. K. Schwartz, et al. Flavopiridol Targets c-KIT Transcription and Induces Apoptosis in Gastrointestinal Stromal Tumor Cells Cancer Res., June 1, 2006; 66(11): 5858 - 5866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Litz and G. W. Krystal Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1{alpha} activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol. Cancer Ther., June 1, 2006; 5(6): 1415 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fuckar, A. Dekanic, S. Stifter, E. Mustac, M. Krstulja, F. Dobrila, and N. Jonjic VEGF Expression is Associated with Negative Estrogen Receptor Status in Patients with Breast Cancer International Journal of Surgical Pathology, January 1, 2006; 14(1): 49 - 55. [Abstract] [PDF]
|
|
|
|
 |
|
 M Korja, J Finne, T T Salmi, H Haapasalo, M Tanner, and J Isola No GIST-type c-kit gain of function mutations in neuroblastic tumours J. Clin. Pathol., July 1, 2005; 58(7): 762 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Beppu, K. Nakamura, W. M. Linehan, A. Rapisarda, and C. J. Thiele Topotecan Blocks Hypoxia-Inducible Factor-1{alpha} and Vascular Endothelial Growth Factor Expression Induced by Insulin-Like Growth Factor-I in Neuroblastoma Cells Cancer Res., June 1, 2005; 65(11): 4775 - 4781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Basciani, M. Brama, S. Mariani, G. De Luca, M. Arizzi, L. Vesci, C. Pisano, S. Dolci, G. Spera, and L. Gnessi Imatinib Mesylate Inhibits Leydig Cell Tumor Growth: Evidence for In vitro and In vivo Activity Cancer Res., March 1, 2005; 65(5): 1897 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sihto, M. Sarlomo-Rikala, O. Tynninen, M. Tanner, L. C. Andersson, K. Franssila, N. N. Nupponen, and H. Joensuu KIT and Platelet-Derived Growth Factor Receptor Alpha Tyrosine Kinase Gene Mutations and KIT Amplifications in Human Solid Tumors J. Clin. Oncol., January 1, 2005; 23(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Uccini, O. Mannarino, H. P. McDowell, U. Pauser, R. Vitali, P. G. Natali, P. Altavista, T. Andreano, S. Coco, R. Boldrini, et al. Clinical and Molecular Evidence for c-kit Receptor as a Therapeutic Target in Neuroblastic Tumors Clin. Cancer Res., January 1, 2005; 11(1): 380 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Katzenstein, S. L. Cohn, R. M. Shore, D. M.E. Bardo, P. R. Haut, M. Olszewski, J. Schmoldt, D. Liu, A. W. Rademaker, and M. Kletzel Scintigraphic Response by 123I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma J. Clin. Oncol., October 1, 2004; 22(19): 3909 - 3915. [Abstract] [Full Text] [PDF]
|
|